Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to stop ICU muscle wasting

NCT ID NCT05919940

Recruiting now Disease control Sponsor: Technical University of Munich Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving ICU patients extra protein and activating their muscles early (using electrical stimulation and movement) can prevent severe muscle loss. About 40 critically ill adults on ventilators will take part. The goal is to see if this approach helps patients keep muscle mass and strength, potentially improving recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENERGY MALNUTRITION PROTEIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

critical illness polyneuropathy metabolic disease Morphological and Microscopic Findings muscular atrophy protein-energy malnutrition

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENERGY MALNUTRITION PROTEIN ICU ACQUIRED WEAKNESS METABOLIC DISTURBANCE MORPHOLOGICAL AND MICROSCOPIC FINDINGS MUSCLE ATROPHY QUALITY OF LIFE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Charité - Universitätsmedizin Berlin

    ACTIVE_NOT_RECRUITING

    Berlin, State of Berlin, 10117, Germany

  • Klinikum rechts der Isar, School of Medicine, Technical Universtity of Munich

    ACTIVE_NOT_RECRUITING

    Munich, Bavaria, 81675, Germany

  • Medical University of Vienna

    RECRUITING

    Vienna, State of Vienna, 1090, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, 89070, Germany

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.